Shelf life (days): 1460.0
Formulation: A solid
Formal Name: 6-(2,6-dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methyl-pyrido[2,3-d]pyrimidin-7(8H)-one
Purity: ≥98%
Formula Markup: C26H27Cl2N5O2
Formula Weight: 512.4
CAS Number: 185039-89-8
Notes: PD 166285 is a tyrosine kinase inhibitor.{63262} It inhibits Src, FGFR1, EGFR, and PDGFRβ (IC50s = 8.4, 39.3, 87.5, and 98.3 nM, respectively), as well as WEE1 (IC50 = 24 nM).{63262,63263} PD 166285 inhibits PDGF- or EGF-induced receptor autophosphorylation in vascular smooth muscle cells (VSMCs) and A431 cells, respectively, and bFGF-induced tyrosine phosphorylation in Sf9 cells (IC50s = 6.5, 1,600, and 97.3 nM, respectively).{63262} It also inhibits chemotaxis and growth of, as well as adhesion to vitronectin by, VSMCs (IC50s = 80-120 nM). PD 166285 inhibits radiation-induced cell cycle arrest at the G2/M phase and enhances radiation-induced cell death in HT-29 cells.{63263} In vivo, PD 166285 (1, 5, and 10 mg/kg) inhibits angiogenesis and induces tumor regression in a 16c murine mammary carcinoma model when administered in combination with photodynamic therapy (PDT).{63264}
Deutsch
English
